Gene Therapy for Lung Cancer

Thoracic Surgery Clinics

Volumn 16, Issue 4, 2006, Pages 397-419

  Toloza, Eric M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 5 AZA 2' DEOXYCYTIDINE; ACICLOVIR; ADVEXIN; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARBOPLATIN; CHOLESTEROL; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOCETAXEL; FR 901228; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; K RAS PROTEIN; LIPOSOME; MELANOMA DIFFERENTIATION ASSOCIATED GENE 7 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 4; OBP 301; PACLITAXEL; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; SECONDARY LYMPHOID TISSUE CHEMOKINE; SKP 2 PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VIRUS PROTEIN;

ADENOVIRUS VECTOR; CANCER RESISTANCE; CLINICAL TRIAL; DRUG FEVER; FAS GENE; FHIT GENE; FUS1 GENE; GENE; GENE ACTIVATION; GENE DISRUPTION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SUICIDE GENE THERAPY; TARGET CELL; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

CELL TRANSFORMATION, NEOPLASTIC; GENE THERAPY; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 35348846075     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2006.08.001     Document Type: Review

References (155)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
3. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
5. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350 (2004) 351-360
6. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599 (Abstract LBA4). Proc Am Soc Clin Oncol, New Orleans (LA), June 5-8, 2004.
7. Shepherd F.A., Pereira J., Ciuleanu T.E., et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial (Abstract 7022). J Clin Oncol 22 (2004) 7022
8. Toloza E.M., Roth J.A., Swisher S.G., et al. Molecular events in bronchogenic carcinoma and their implications for therapy. Semin Surg Oncol 18 2 (2000) 91-99
9. Ihde D.C., and Minna J.D. Non-small cell lung cancer, part I. Biology, diagnosis, and staging. Curr Probl Cancer 15 (1991) 61-104
10. Sundaresan V., Reeve J.G., Wilson B., et al. Flow cytometric and immunohistochemical analysis of p62c-myc oncoprotein in the bronchial epithelium of lung cancer patients. Anticancer Res 11 (1991) 2111-2116
11. Gosney J.R., Field J.K., Gosney M.A., et al. c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types. Anticancer Res 10 (1990) 623-628
12. Song J.S. Enhanced expression of apoptin by the Myc-Max binding motif and SV40 enhancer for SCLC gene therapy. Biosci Biotechnol Biochem 69 1 (2005) 51-55
13. Song J.S. Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer. Biosci Biotechnol Biochem 69 1 (2005) 56-62
14. Salgia R., and Skarin A.T. Molecular abnormalities in lung cancer. J Clin Oncol 16 3 (1998) 1207-1217
15. Gibbs J. Pharmacological probes of ras function. Semin Cancer Biol 6 (1992) 383-390
16. Mitsudomi T., Steinberg S.M., Oie H.K., et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51 (1991) 4999-5002
17. Sugio K., Kishimoto Y., Virmani A.K., et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54 (1994) 5811-5815
18. Phillips D.H., Hewer A., Martin C.N., et al. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336 (1988) 790-792
19. Randerath E., Miller R.H., Mittal D., et al. Covalent DNA damage in tissues of cigarette smokers as determined by 32P-postlabeling assay. J Natl Cancer Inst 81 (1989) 341-347
20. Reddel R.R., Ke Y., Kaighn M.E., et al. Human bronchial epithelial cells neoplastically transformed by v-Ki-ras: altered response to inducers of terminal squamous differentiation. Oncogene Res 3 (1988) 401-408
21. Vaele D., Kerr N., Gibson G.J., et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68 (1993) 162-165
22. Kern J.A., Slebos J.C., Top B., et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93 (1994) 516-520
23. Fontanini G., Vignati S., Bigini D., et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A (1995) 178-183
24. Pavelic J., Pavelic L., Karadza J., et al. Insulin-like growth factor family and combined anti-sense approach in therapy of lung carcinoma. Mol Med 8 3 (2002) 149-157
25. Hochscheid R., Jaques G., and Wegmann B. Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol 166 3 (2000) 553-563
26. Tseng J.E., Kemp B.L., Khuri F.R., et al. Loss of FHIT is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 59 (1999) 4798-4803
27. Ito I., Ji L., Tanaka F., et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent anti-tumor activity against human lung cancer in vivo. Cancer Gene Ther 11 11 (2004) 733-739
28. Brambilla E., and Brambilla C. p53 and lung cancer. Pathol Biol (Paris) 45 10 (1997) 852-863
29. Walker C., Robertson L.J., Myskow M.W., et al. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 70 (1994) 297-303
30. Gerwin B.I., Spillare E., Forrester K., et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci USA 89 (1992) 2759-2763
31. Denissenko M.F., Pao A., Tang M.S., et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274 (1996) 430-432
32. Roth J.A., Grammer S.F., Swisher S.G., et al. Gene replacement strategies for treating non-small cell lung cancer. Semin Radiat Oncol 10 4 (2000) 333-342
33. Greenblatt M.S., Reddel R.R., and Harris C.C. Carcinogenesis, and cellular and molecular biology of lung cancer. In: Roth J.A., Ruckdeschel J.C., and Weisenburger T.H. (Eds). Thoracic oncology (1995), WB Saunders Company, Philadelphia 5-25
34. Shackney S.E., Smith C.A., Pollice A., et al. Genetic evolutionary staging of early non-small cell lung cancer: the p53-HER-2/neu-ras sequence. J Thorac Cardiovasc Surg 118 (1999) 259-269
35. Ten Have-Opbroek A.A., Benfield J.R., Hammond W.G., et al. In favour of an oncofoetal concept of bronchogenic carcinoma development. Histol Histopathol 9 375 (1994) 384
36. Woll P.J., and Hart I.R. Gene therapy for lung cancer. Ann Oncol 6 Suppl 1 (1995) 73-77
37. Lee H.Y., Suh Y.A., Lee J.I., et al. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res 8 9 (2002) 2970-2975
38. Ito I., Began G., Mohiuddin I., et al. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther 7 3 (2003) 409-418
39. Gopalan B., Ito I., Branch C.D., et al. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 3 6 (2004) 647-657
40. Ilies M.A., Johnson B.H., Makori F., et al. Pyridinium cationic lipids in gene delivery: an in vitro and in vivo comparison of transfection efficiency versus a tetraalkylammonium congener. Arch Biochem Biophys 435 1 (2005) 217-226
41. Cristiano R.J., and Roth J.A. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 3 1 (1996) 4-10
42. Batra R.K., Dubinett S.M., Henkle B.W., et al. Adenoviral gene transfer is inhibited by soluble factors in malignant pleural effusions. Am J Respir Cell Mol Biol 22 5 (2000) 613-619
43. Su S., Watanabe A., Yamamoto M., et al. Mutations in p53 cDNA sequence introduced by retroviral vector. Biochem Biophys Res Commun 340 2 (2006) 567-572
44. Qin M., Chen S., Yu T., et al. Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts. Clin Cancer Res 9 13 (2003) 4992-4999
45. Batra R.K., Bernal R.M., and Sharma S. Identifying obstacles to viral gene therapy for lung cancer. Malignant pleural effusions as a paradigm. Methods Mol Med 75 (2003) 545-559
46. Bernal R.M., Sharma S., Gardner B.K., et al. Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. Clin Cancer Res 8 6 (2002) 1915-1923
47. Eto Y., Gao J.Q., Sekiguchi F., et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 7 5 (2005) 604-612
48. Lee C.T., Park K.H., Yanagisawa K., et al. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 64 18 (2004) 6660-6665
49. Harada N., Maniwa Y., Yoshimura M., et al. E1B-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence of apoptosis. Oncol Rep 14 5 (2005) 1155-1163
50. Watanabe T., Hioki M., Fujiwara T., et al. Histone deacetylase inhibitor FR901228 enhances the anti-tumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 312 3 (2006) 256-265
51. Shi J., Zheng D., Liu Y., et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 65 5 (2005) 1687-1692
52. Yoo J., Choi S., Hwang K.S., et al. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J Gene Med 8 2 (2006) 163-174
53. Rosell R., Cecere F., Cognetti F., et al. Future directions in the second-line treatment of non-small cell lung cancer. Semin Oncol 33 1, Suppl 1 (2006) S45-S51
54. Prins J., de Vries E.G., and Mulder N.H. Anti-sense of oligonucleotides and the inhibition of oncogene expression. Clin Oncol (R Coll Radiol) 5 4 (1993) 245-252
55. Roth J.A., Mukhopadhyay T., Tainsky M.A., et al. Molecular approaches to prevention and therapy of aerodigestive tract cancers. J Natl Cancer Inst Monogr 13 (1992) 15-21
56. Zhang W.W., and Roth J.A. Anti-oncogene and tumor suppressor gene therapy-examples from a lung cancer animal model. In Vivo 8 5 (1994) 755-769
57. Mukhopadhyay T., Tainsky M., Cavender A.C., et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by anti-sense RNA. Cancer Res 51 (1991) 1744-1748
58. Zhang Y., Mukhopadhyay T., Donehower L.W., et al. Retroviral vector-mediated transduction of K-ras anti-sense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4 (1993) 451-460
59. Georges R.N., Mukhopadhyay T., Zhang Y., et al. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral anti-sense K-ras construct. Cancer Res 53 (1993) 1743-1746
60. Schrump D.S., Chen A., and Consoli U. Inhibition of lung cancer proliferation by anti-sense cyclin D. Cancer Gene Ther 3 2 (1996) 131-135
61. Lee C.T., Park K.H., Adachi Y., et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate anti-tumor effects on lung cancer. Cancer Gene Ther 10 1 (2003) 57-63
62. Lee C.T., Wu S., Gabrilovich D., et al. Anti-tumor effects of an adenovirus expressing anti-sense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56 13 (1996) 3038-3041
63. Fire A., Xu S., Montgomery M.K., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 6669 (1998) 806-811
64. Bernstein E., Caudy A.A., Hammond S.M., et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 6818 (2001) 363-366
65. Hamilton A.J., and Baulcombe D.C. A species of small anti-sense RNA in posttranscriptional gene silencing in plants. Science 286 5441 (1999) 950-952
66. Hammond S.M., Bernstein E., Beach D., et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 6775 (2000) 293-296
67. Pham J.W., Pellino J.L., Lee Y.S., et al. Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila. Cell 117 1 (2004) 83-94
68. Zamore P.D., Tuschl T., Sharp P.A., et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 1 (2000) 25-33
69. Hutvagner G., and Zamore P.D. RNAi: nature abhors a double-strand. Curr Opin Genet Dev 12 2 (2002) 225-232
70. Sumimoto H., Yamagata S., Shimizu A., et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 12 1 (2005) 95-100
71. Zhang Y.A., Nemunaitis J., and Tong A.W. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Mol Biotechnol 15 1 (2000) 39-49
72. Zhang Y.A., Nemunaitis J., Scanlon K.J., et al. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther 7 23 (2000) 2041-2050
73. Chang J.Y., Xia W., Shao R., et al. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene 13 7 (1996) 1405-1412
74. Roth J.A. Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum Gene Ther 7 7 (1996) 875-889
75. Roth J.A. Gene replacement strategies for lung cancer. Curr Opin Oncol 10 2 (1998) 127-132
76. Jin X., Nguyen D., Zhang W.W., et al. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 55 (1995) 3250-3253
77. Xu H.J., Zhou Y., Seigne J., et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 56 10 (1996) 2245-2249
78. Willey J.C., and Harris C.C. Cellular and molecular biological aspects of human bronchogenic carcinogenesis. Crit Rev Oncol Hematol 10 (1990) 181-209
79. Cai D.W., Mukhopadhyay T., Liu Y., et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 4 (1993) 617-624
80. Fujiwara T., Grimm E.A., Mukhopadhyay T., et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53 18 (1993) 4129-4133
81. Nguyen D.M., Wiehle S.A., Koch P.E., et al. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther 4 3 (1997) 191-198
82. Zhang W.W., Fang X., Mazur W., French B.A., et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1 1 (1994) 5-13
83. Fujiwara T., Cai D.W., Georges R.N., et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86 19 (1994) 1458-1462
84. Ramesh R., Saeki T., Templeton N.S., et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3 3 (2001) 337-350
85. Takahashi T., Carbone D., Takahashi T., et al. Wild type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52 (1992) 2340-2343
86. Nishizaki M., Fujiwara T., Tanida T., et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5 5 (1999) 1015-1023
87. Roth J.A. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53. Hum Gene Ther 7 7 (1996) 861-874
88. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2 9 (1996) 985-991
89. Roth J.A. Restoration of tumour suppressor gene expression for cancer. Forum 8 4 (1998) 368-376
90. Roth J.A., Swisher S.G., and Meyn R.E. p53 tumor suppressor gene therapy for cancer. Oncology (Huntington) 13 10, Suppl 5 (1999) 148-154
91. Swisher S.G., and Roth J.A. Gene therapy in lung cancer. Curr Oncol Rep 2 1 (2000) 64-70
92. Roth J.A. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 7 8 (1996) 1013-1030
93. Yen N., Ioannides C.G., Xu K., et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7 4 (2000) 530-536
94. Swisher S.G., Roth J.A., Nemunaitis J., et al. Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 91 (1991) 763-771
95. Swisher S.G., Roth J.A., Nemunaitis J., et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91 9 (1999) 763-771
96. Weill D., Mack M., Roth J., et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 118 4 (2000) 966-970
97. Roth J.A., Swisher S.G., Merritt J.A., et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25 3, Suppl 8 (1998) 33-37
98. Fujiwara T., Tanaka N., Kanazawa S., et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 24 11 (2006) 1689-1699
99. Documents O.B.A. Summary table: human gene marker/therapy clinical protocols. Last updated: 5/31/02. Hum Gene Ther 13 18 (2002) 2251-2337
100. Kagawa S., Pearson S.A., Ji L., et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther 7 1 (2000) 75-79
101. Joshi U.S., Chen Y.Q., Kalemkerian G.P., et al. Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer. Cancer Gene Ther 5 3 (1998) 183-191
102. Saeki T., Mhashilkar A., Chada S., et al. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther 7 23 (2000) 2051-2057
103. Ji L., Fang B., Yen N., et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59 14 (1999) 3333-3339
104. Nishizaki M., Sasaki J., Fang B., et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 64 16 (2004) 5745-5752
105. Shinoura N., Ohashi M., Yoshida Y., et al. Construction, propagation, and titer estimation of recombinant adenoviruses carrying proapoptic genes. Hum Gene Ther 9 (1998) 2683-2689
106. Kagawa S., He C., Gu J., et al. Anti-tumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61 8 (2001) 3330-3338
107. Huang X., Lin T., Gu J., et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 9 20 (2002) 1379-1386
108. Cai D.W., Mukhopadhyay T., and Roth J.A. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 2 3 (1995) 199-205
109. Batra R.K., Guttridge D.C., Brenner D.A., et al. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. Am J Respir Cell Mol Biol 21 2 (1999) 238-245
110. Kim H.W., Park I.K., Cho C.S., et al. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res 64 21 (2004) 7971-7976
111. Addison C.L., Arenberg D.A., Morris S.B., et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 11 2 (2000) 247-261
112. Cui R., Takahashi K., Takahashi F., et al. Endostatin gene transfer in murine lung carcinoma cells induces vascular endothelial growth factor secretion resulting in up-regulation of in vivo tumorigenecity. Cancer Lett 232 2 (2006) 262-271
113. Hasegawa Y., Emi N., Shimokata K., et al. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors. Am J Respir Cell Mol Biol 8 6 (1993) 655-661
114. Ram Z., Culver K.W., Walbridge S., et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53 1 (1993) 83-88
115. Rom W.N., and Woo S.L.C. Phase I trial of adenoviral vector delivery of the Herpes simplex thymidine kinase gene by intratumoral injection followed by intravenous ganciclovir in patients with advanced non-small cell lung cancer. Hum Gene Ther 10 3 (1999) 491
116. Huang M., Batra R.K., Kogai T., et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 8 8 (2001) 612-618
117. Dubinett S.M., and Kradin R.L. Cytokine immunotherapy of non-small cell lung cancer. Reg Immunol 5 3-4 (1993) 232-243
118. Lotze M.T., Rubin J.T., Carty S., et al. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5 1 (1994) 41-55
119. Miller A.R., McBride W.H., Moen R.C., et al. Interleukin-2 producing fibroblast cell line abrogates tumorigenicity in a murine tumor model: an approach to genetically engineered tumor vaccines. Surg Forum 49 (1993) 512-514
120. Tsai S.C., Gansbacher B., Tait L., et al. Induction of anti-tumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 85 7 (1993) 546-553
121. Esandi M.C., van Someren G.D., Bout A., et al. IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using "cracked" adenoproducer cells. Gene Ther 5 6 (1998) 778-788
122. Porgador A., Tzehoval E., Katz A., et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52 (1992) 3679-3686
123. Sharma S., Wang J., Huang M., et al. Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances anti-tumor reactivity. Cancer Gene Ther 3 5 (1996) 302-313
124. Cassileth P.A., Podack E., Sridhar K., et al. Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum Gene Ther 6 3 (1995) 369-384
125. Dranoff G., and Salgia R. A phase I study of vaccination with autologous, lethally irradiated non-small cell lung carcinoma cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 9 6 (1998) 915
126. Nemunaitis J., Sterman D., Jablons D., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96 (2004) 326-331
127. Yang S.C., Batra R.K., Hillinger S., et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 66 6 (2006) 3205-3213
128. Wilderman M.J., Kim S., Gillespie C.T., et al. Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer. Mol Ther 13 5 (2006) 910-917
129. Busche A., Goldmann T., Naumann U., et al. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther 17 2 (2006) 135-146
130. Qin M., Escuadro B., Sharma S., et al. Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells. Am J Respir Cell Mol Biol 32 3 (2005) 211-217
131. Mukhopadhyay T., and Roth J.A. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 17 2 (1998) 241-246
132. Kataoka M., Schumacher G., Cristiano R.J., et al. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 58 21 (1998) 4761-4765
133. Sharma S., Miller P.W., Stolina M., et al. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4 12 (1997) 1361-1370
134. Miller P.W., Sharma S., Stolina M., et al. Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther 5 6 (1998) 380-389
135. Sharma S., Yang S.C., Batra R.K., et al. Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer models. Methods Mol Med 75 (2003) 711-722
136. Miller P.W., Sharma S., Stolina M., et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 11 1 (2000) 53-65
137. Antonia S. Treatment of small cell lung cancer patients in partial remission or at relapse with B7-1 gene-modified autologous tumor cells as a vaccine with systemic interferon gamma. Hum Gene Ther 9 16 (1998) 2452
138. Nguyen D.M., Spitz F.R., Yen N., et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112 5 (1996) 1372-1376
139. Fujiwara T., Grimm E.A., Mukhopadhyay T., et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54 9 (1994) 2287-2291
140. Cristiano R.J., Xu B., Nguyen D., et al. Viral and nonviral gene delivery vectors for cancer gene therapy. Cancer Detect Prev 22 5 (1998) 445-454
141. Gomyo Y., Sasaki J., Branch C., et al. 5-Aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23 40 (2004) 6779-6787
142. Merritt J.A., Roth J.A., and Logothetis C.J. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 28 5, Suppl 16 (2001) 105-114
143. Swisher S.G., and Roth J.A. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am 11 3 (2002) 521-535
144. Roth J.A., Grammer S.F., Swisher S.G., et al. P53 gene replacement for cancer-interactions with DNA damaging agents. Acta Oncol (Madr) 40 6 (2001) 739-744
145. Roth J.A., Grammer S.F., Swisher S.G., et al. Gene therapy approaches for the management of non-small cell lung cancer. Semin Oncol 28 4, Suppl 14 (2001) 50-56
146. Dobbs T.W. A phase II gene therapy study in patients with non-small cell lung cancer using SCH58500 (eAD/P53) in combination with chemotherapy for multiple cycles. Hum Gene Ther 9 16 (1998) 2429
147. Kawabe S., Roth J.A., Wilson D.R., et al. Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 19 47 (2000) 5359-5366
148. Swisher S.G., Roth J.A., Komaki R., et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9 1 (2003) 93-101
149. Nishizaki M., Meyn R.E., Levy L.B., et al. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 7 9 (2001) 2887-2897
150. Swisher S.G., Roth J.A., and Carbone D.P. Genetic and immunologic therapies for lung cancer. Semin Oncol 29 1, Suppl 4 (2002) 95-101
151. Swisher S.G., and Roth J.A. p53 Gene therapy for lung cancer. Curr Oncol Rep 4 4 (2002) 334-340
152. Greenberger J.S., Bahri S., Jett J., et al. Considerations in optimizing radiation therapy for non-small cell lung cancer. Chest 113 1 Suppl (1998) 46S-52S
153. Epperly M.W., Defilippi S., Sikora C., et al. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 7 12 (2000) 1011-1018
154. Guo H., Epperly M.W., Bernarding M., et al. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis lung carcinomas. In Vivo 17 1 (2003) 13-21
155. Usuda J., Okunaka T., Furukawa K., et al. Increased cytotoxic effects of photodynamic therapy in IL-6 gene transfected cells via enhanced apoptosis. Int J Cancer 93 4 (2001) 475-480